Clinical trial · no report yet · Phase 1
NCT03802695
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- NCT03802695 ↗
- Recruiting
- Orca Biosystems, Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Acute Myeloid Leukemia; Myelodysplastic Syndromes; Mixed Phenotype Acute Leukemia; Acute Lymphoblastic Leukemia
- Interventions
- OrcaGraft (Orca-Q)
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Arm C · Experimental
- Arm D · Experimental
- Arm E · Experimental
- Arm F · Experimental
- Enrollment
- 300 (estimated)
- Primary outcomes
- Dose Limiting Toxicities through Day +28 (dose escalation)
- Primary Graft failure through Day +28 (dose expansion)
- Sponsor
- Orca Biosystems, Inc.
- Start
- Apr 8, 2019
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03802695 · updated Sep 29, 2026
Publications
linked from the registry- O'Neal J, Mavers M, Jayasinghe RG, DiPersio JF. Traversing the bench to bedside journey for iNKT cell therapies. Front Immunol. 2024 Aug 7;15:1436968. doi: 10.3389/fimmu.2024.1436968. eCollection 2024. PubMed 39170618